Danaher (DHR) - Get Report shares were down 1.2% to $136.84 Thursday after the life-sciences company beat Wall Street's third-quarter earnings estimates but offered disappointing guidance.

The Washington company reported net income of $648.4 million or 89 cents a share, down from $663.7 million, or 93 cents, in the year-earlier quarter. Adjusted profit was $1.16, beating FactSet's analyst consensus of $1.15.

Sales totaled $5.04 billion, up from $4.85 billion a year earlier and ahead of FactSet's call for $5.02 billion.

Looking ahead, Danaher said it expected fourth-quarter adjusted profit to range $1.32 to $1.35 a share, missing FactSet's forecast of $1.37.

In addition, the company reduced its 2019 guidance to $4.74 to $4.77, after raising it to $4.75 to $4.80 in July.

Earlier this year Danaher bought General Electric's (GE) - Get Report  biopharma division for about $21 billion.

On Monday, Danaher said it had agreed to sell three of its life-sciences-tools businesses to Sartorius Stedim Biotech for about $750 million cash, which the company said was prompted by the GE agreement.

Thomas P. Joyce, Jr., president and CEO, said in a statement that Danaher raised about $6.8 billion in euro-denominated debt in September to be used to fund the acquisition.

Save 57% during our Halloween Sale. Don't let this market haunt you and join Jim Cramer's Investment Club, Action Alerts PLUS. Click here to sign up!